Claims for Patent: 11,707,450

Summary for Patent: 11,707,450

Title:	Stable pharmaceutical compositions of bendamustine
Abstract:	Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
Inventor(s):	Harish Govindaraja Setty CHINNARI, Somashekhar BATTINI, Sumitra Ashokkumar PILLAI, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US17/877,476
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,707,450
Patent Claims:	1. A method of treating chronic lymphocytic leukemia or indolent B cell non-Hodgkin's lymphoma comprising administering to a patient in need thereof a therapeutically effective amount of a liquid composition comprising: a) about 25 mg/mL of bendamustine or a pharmaceutically acceptable salt thereof; and b) at least one non-aqueous solvent; wherein the at least one non-aqueous solvent is selected from the group consisting of alcohol, glycerine, polyethylene glycol (PEG), dimethylacetamide, N-methyl-pyrrolidone, dimethyl sulfoxide, and mixtures thereof; wherein a level of total impurities in said liquid composition is not more than 5% w/w when stored at a temperature from about 2° C. to about 8° C. for 6 months as measured by HPLC; wherein said liquid composition is diluted with a parenterally acceptable aqueous diluent prior to administration to provide a diluted liquid composition; wherein a total volume of the diluted liquid composition is about 250 mL or less; wherein the diluted liquid composition is administered over a period of less than or equal to about 20 minutes; and wherein the liquid composition and the diluted liquid composition are antioxidant-free. 2. The method according to claim 1, wherein the liquid composition has a pH ranging from about 3.0 to about 5.0. 3. The method according to claim 2, wherein the liquid composition has a pH of about 3.2. 4. The method according to claim 1, wherein the polyethylene glycol (PEG) is PEG-400. 5. The method according to claim 4, wherein the polyethylene glycol (PEG) has a pH from about 6.0 to about 11. 6. The method according to claim 1, wherein the alcohol is a dehydrated alcohol. 7. The method according to claim 1, wherein the bendamustine or a pharmaceutically acceptable salt thereof is bendamustine hydrochloride. 8. The method according to claim 1, wherein the at least one non-aqueous solvent comprises a mixture of alcohol and polyethylene glycol (PEG). 9. The method according to claim 1, further comprising a pH adjuster selected from the group consisting of sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium carbonate, tromethamine, sodium linoleate, sodium oleate, potassium carbonate, potassium linoleate, potassium oleate, and mixtures thereof. 10. The method according to claim 9, wherein the pH adjuster comprises sodium hydroxide in an amount less than 0.5 mg/mL.